Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Above 50 Day Moving Average - Here's What Happened

Key Points

• Northwest Biotherapeutics shares have recently surpassed their 50-day moving average of $0.26, trading as high as $0.27 before settling at $0.25.
• The company has a market capitalization of $370.78 million and reported a loss of ($0.01) earnings per share and revenue of $0.38 million in its last earnings report.
• Northwest Biotherapeutics specializes in developing personalized immune therapies for cancer, utilizing its DCVax platform technology to engage patients' immune systems against the disease.

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report)'s stock price passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $0.26 and traded as high as $0.27. Northwest Biotherapeutics shares last traded at $0.25, with a volume of 2,246,899 shares.

Northwest Biotherapeutics Stock Performance

The firm has a market capitalization of $363.79 million, a PE ratio of -3.51 and a beta of -1.12. The business's fifty day simple moving average is $0.26 and its 200-day simple moving average is $0.26.

Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $0.38 million during the quarter.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.